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Introduction
Cancer is a disease characterized by the presence of mutated 
cells that continue to divide uncontrollably. Cancerous, or ma-
lignant, tumors, can spread to other parts of the body especially 
via the lymph system which can act like a cancer highway, and 
new tumors can then form in places far from the original tumor 
source (What is Cancer 2015). These tumors can have negative 
health effects and in many cases can be life threatening.
According to the World Health Organization more than 14 mil-
lion new cancer cases were diagnosed in 2012 and there were 
more than 8 million deaths attributed to cancer. Additionally, 
the American Cancer Society projects the number of new can-
cer cases in the United States in 2015 to exceed 1.5 million and 
the number of deaths to exceed a half million. 
Radiotherapy, a common cancer treatment, works by directing 
high energy beams, including x-rays and gamma rays, at cancer 
cells to disrupt their DNA and ultimately result in cell death 
(“Radiation Therapy”). Although radiation therapy can be suc-
cessful at eradicating cancerous cells, relapse is a common 
problem because a few cells, or even just one cell, left behind 
can continue to divide and pose a serious health risk (Wayteck 
et. al., 2014). 
To combat the problem of relapse, chemotherapy is com-
monly prescribed to ensure that all cancerous cells are erad-
icated. Chemotherapy works by killing all rapidly dividing cells 
(“Chemotherapy”). However, chemotherapy has many unwanted 
side effects as it does not differentiate between healthy rapidly di-
viding cells and cancerous rapidly dividing cells. This effects many 
different systems within the body and can cause anemia, hair loss, 
infection and other unhealthy and unwanted symptoms. 
Another form of treatment, immunotherapy, works by using 
immune elements to target cancerous cells through recogni-
tion of cancer antigens. There are two different ways of rec-
ognizing cancerous cells through antigens. One way is through 
tumor specific antigens which are expressed solely in cancer-
ous tumor cells, while the other involves overexpressed anti-
gens which more abundant in cancerous tumor cells than in 
healthy cells. This method of treatment aims to avoid the side 
effects of chemotherapy by targeting only cancerous cells and 
to also thwart the problem of relapse seen in radiation therapy 
(Wayteck et. al., 2014). 
Passive immunotherapy uses stimulatory factors such IL-2 
which is injected into the tumor area to stimulate anti-tumor 
T cells to proliferate, activate, and increase effector functions 
(Wayteck et. al., 2014). Active immunotherapy, on the other 
hand, involves CD 8 and CD4 T cells that are primed to rec-
ognize specific cancerous antigens and thereby direct immune 
cells to target and kill these cancerous cells. This report dis-
cusses the effectiveness of active immunnotherapy in general 
and, specifically, a branch of active immunotherapy called adop-
tive cell transfer. 
Methods
To research the effectiveness of active immunotherapy and spe-
cifically adoptive cell transfer, relevant information was gathered 
from many databases and journals. Those databases included: 
the Touro College Library database, Proquest Science Journals, 
Pub MEDLINE (EBSCO), and Oxford Journals. The information 
gathered was narrowed further and analyzed to glean an un-
derstanding of the effectiveness of these treatment protocols.
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Discussion
A recent study indicates that active immunotherapy can be an 
effective treatment for cancerous tumors (Raez, et. al. 2003). This 
study assessed the impact and response of CD8 T cells to tumor-
cell-based allogeneic vaccines in patients with advanced non-small-
cell carcinoma, commonly known as lung cancer. However, the 
selection of patients with advanced stages of non-small-cell car-
cinoma may have resulted in reduced effectiveness of treatment, 
as cancerous cells may have been too numerous for the body’s 
immune system to handle. Similarly, as only patients previously 
unresponsive to conventional treatments like chemotherapy and 
radiation therapy were studied, the results may have been lower 
than they might be had the body’s ability to fight off harmful cells 
not already been undermined.
Vaccinations were delivered in three courses.  After com-
pletion of the first course, only patients with stable disease 
progression or positive response against non-small-cell car-
cinoma as determined by CT scan, coupled with low toxicity, 
continued to a second course of vaccination. Again, patients 
with no tumor progression and non-life threatening levels of 
toxicity continued on to a third course of vaccination (Table 
1). The patients were evaluated at the beginning and end of 
each course to study clinical effects and to determine toxicity 
levels (Raez, et. al. 2003). 
The results of the above study, as shown in Table 2, indicate an 
increase in CD8 T cell response in all but one patient. Clinically, 
however, the results were less profound. Only 27% of the patients 
















1005 A1 PD 190 C+R 10 - 0 190 ND ND
1012 A1 NE NE C 15 - 0.2 ND ND ND
1001 A2 PD 25 C+S 18 - 0 25 ND ND
1002 A2 PD 1.6 C+S 22 - 41 65 ND ND
1009 A2 PD 6.5 C 3 - 2 13 ND ND
1010 A2 PR 41 S 27+ 3 3.8 46 88 157
1011 A2 PD 19 C 11 - 3 30 57 ND
1013 A2 PD 34 C+R+S 2 - 5.2 164 178 ND
1014 A2 SD 19 C+S 13+ 3 1.6 30 30 25
1015 A2 PD 0 C+R 7 - 0 0 ND ND
1003 non SD 134 S 31+ 26+ 1 134 113 84
1004 non SD 424 C+R 23 11 0 424 232 >450
1006 non PD 9.3 C+S 30+ - 16 150 ND ND
1007 non SD 14 C+R+S 29+ 23+ 1.2 2.8 0.8 0/17
1008 non PD 32 C 6 - 5.6 178 ND ND
PD=progressive disease; PR=partial response; SD=stable disease; ND=not determined; C=chemotherapy; R=radiation therapy; S=supportive 
care; NE=not evaluable
Course 1 Course 2 Course 3









showed stable disease progression while another 7% showed a 
partial response. This total clinical response of 33% suggests that 
immunotherapy may be a viable option but requires further study 
to assess clinical effectiveness. (Raez, et. al. 2003)
The vaccine used in this study was developed by Dr. N. Savaraj 
through modification of a cell line harnessed from a patient in 1994. 
The cells were rendered incapable of colonizing ensuring they 
would not cause any harm to study participants. However, perhaps 
a more effective albeit more expensive method, demonstrated at 
the Johns Hopkins School of Medicine (Perica, et.al. 2015), may be 
to extract a patient’s own CD8 T cells from the vicinity of the 
tumor and subsequently culture them in vitro. This would ensure 
that the T cells would be reactive to the patient’s own cancerous 
cells. Using pharmaceuticals to regulate the patient’s regulatory T 
cells, the CD8 T cells harnessed in vitro can be reinserted with free 
rein to target cancerous cells (Perica, et.al. 2015). 
Adoptive cells transfer is a treatment in which immune cells 
harnessed in vitro are transferred to a patient to give him spe-
cific immune functions. To treat cancer patients using adoptive 
cell transfer, a piece of a tumor is removed from the body, so 
that T cells can be removed from the tumor, and stimulated to 
grow rapidly in vitro. These T cells are then infused back into the 
patient to target and kill cancer cells (Figure 1).
When attempted on patients with metastatic melanoma, adop-
tive cell transfer showed potential as an effective treatment 
although admittedly it had limited clinical results. A trial of 20 
metastatic melanoma patients were treated with adoptive cell 
transfer and given IL-2 to stimulate the transferred T cells. The 
results revealed tumor regression in multiple sites in 11 of the 
20 patients studied (Phan, Rosenberg, 2013). However, it should 
be noted that although IL-2 promotes the growth and function 
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suppress these transferred T cells thus countering the intended 
effect and perhaps limiting the overall effectiveness of the treat-
ment. This indicates that adoptive cell transfer may have a place 
in the pursuit of a cure for cancer but it does require some 
further fine tuning. 
Depletion of immune cells and other immune elements before 
adoptive cell transfer of CD 8 T cells in mice has been shown to 
increase the effectiveness of transferred T cells (Gattinoni et. al., 
2005).  It has been proposed that depleting the immune system 
of its natural elements keeps regulatory T cells from turning off 
anti-cancer CD 8 T cells transferred during adoptive cell trans-
fer. Additionally, adoptive cell transfer helps lower the immune 
system’s tolerance of the cancerous “self-antigens” by selecting 
and activating highly specific T cells, mostly CD 8 T cells, and by 
changing the body’s internal environment to one that is more 
receptive to these cells. 
A recent study looked at 13 metastatic melanoma patients who 
received immunodepleting chemotherapy specifically targeted 
to regulatory T cells. The patients were then injected with in 
vitro cultured T cells as well as IL-2. Because the patients first 
received immunodepleting chemotherapy, in this study the addi-
tion of IL-2 avoided the adverse effect of activating regulatory T 
cells. This allowed for highly favorable results (Table 3) that were 
significantly more efficient than the results of the study involving 
non-small-cell carcinoma patients. Of the 13 patients, 6 showed 
positive clinical responses, and 4 showed mixed responses con-
sisting of considerable shrinkage of at least one tumor. Although 
the study was relatively small and was limited to melanoma pa-
tients, it nevertheless demonstrates the potential of adoptive 
cell transfer in treating cancer patients (Dudley et. al., 2002).
In a similar trial, metastatic melanoma patients were treated with 
different levels of immunodepletive therapy prior to adoptive cell 
Patient Demographics, Treatments Received, and Clinical Outcomes. 


























3 43/F 4.0 44/58 gp100 5 Brain, cutaneous, 
liver,lung
NR None
4 57/F 3.4 56/52 gp100 9 Cutaneous, subcu-
taneous
PR (2) None
5 53/M 3.0 16/85 Other 7 Brain, lung, lymph 
nodes
NR-mixed None
6 37/F 9.2 65/35 Other 6 Lung, intraperitoneal, 
subcutaneous
PR (15+) None
7 44/M 12.3 61/41 MART-1 7 Lymph nodes, subcu-
taneous
NR-mixed Vitiligo
8 48/M 9.5 48/52 gp100 12 Subcutaneous NR None
9 57/M 9.6 84/43 MART-1 10 Cutaneous, subcu-
taneous
PR (10+) Vitiligo
10 55/M 10.7 96/2 MART-1 12 Lymph nodes, cutane-
ous, subcutaneous
PR (9+) Uveitis
11 29/M 13.0 96/3 MART-1 12 Liver, pericardial, 
subcutaneous
NR-mixed Vitiligo
12 37/F 13.7 72/74 MART-1 11 Liver, lung, gallbladder, 
lymph nodes
NR-mixed None
13 41/F 7.7 92/8 MART-1 11 Subcutaneous NR None
PR = Partial Response, NR = No Response
Table 3
Dudley et. al., 2002 
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transfer in order to establish a level of immunodepletion that would 
best enhance this treatment protocol (Rosenberg et. al., 2011). One 
group of 43 patients received a nonmyeloablative preparative regi-
men, a less toxic method of immunodepletion. A second and third 
group of 25 patients each, received a more toxic total body irradi-
ation of 2 Gy and 12 Gy (Dept. of Homeland Security 15), respec-
tively, in addition to a non-myeloablative preparative regimen. All 
three groups were subsequently treated with adoptive cell transfer 
(Rosenberg et. al., 2011). 
The results of this study (Table 4) showed that at higher levels of 
immunodepletion positive clinical outcomes following adoptive 
cell transfer increased. In the group that received only a non-my-
eloablative preparative regimen, 49% of subjects showed an overall 
response while 5% showed complete response. The group that 
received 2 Gy of total body irradiation exhibited slightly higher in-
cidence of overall response at 52%, but showed a large increase in 
complete response at 20%. The group that received 12 Gy of total 
body irradiation showed a marked overall response of 72% with 
complete response at 40%, indicating that the greater the immuno-
depletion the greater the clinical outcome of adoptive cell transfer 
(Rosenberg et. al., 2011). 
One possible method to increase the overall effectiveness of 
adoptive cell transfer and such positive results is to harness 
a patient’s own CD 8 T cells to ensure that the T cells are as 
specific to the cancer cell antigens as possible to. However, this 
is likely a complicated task as it would require development 
of a “new drug” for every patient. Another method that may 
enhance the results of adoptive cell transfer is to take a sample 
of the patients own cancer cells and test CD 8 T cell reactivity 
to the cancer antigens thereby ensuring a highly reactive T cell 
response.  In another experiment, 20 metastatic melanoma pa-
tients received a less intense form of immunodepletion called 
nonmyeloablative preparative regimen. However, no patient re-
ceived total body irradiation. In this trial, however, T cells were 
taken directly from the actual patients’ tumor and grown quick-
ly in vitro, as opposed to using previously developed anti-tumor 
T cells. This may have helped ensure T cells would be highly 
specific and highly reactive to the patients’ own cancerous cells. 
Of the 20 patients treated, 10 had an overall response, of 
which 2 had a complete remission and 8 had a partial remis-
sion. Additionally, 4 patients had stable disease, and 6 had pro-
gressive disease for an overall response of 70%  (Besser et. 
al., 2010). The results show that nonmyeloablative preparative 
regimen, coupled with adoptive cell transfer that uses cells 
harnessed from patients own tumors can be an effective treat-
ment. Furthermore, analysis of the results may show that the 
results are more positive then what is seen on the surface.  Of 
the 6 patients with progressive disease after treatment, all 6 
started with stage M1c melanoma, which represents the stage 
in which the tumor has traveled to vital organs (excluding the 
lungs) or when the tumor has traveled to other areas and 
the patient shows elevated levels of low-density lipoprotein 
(“How is Melanoma Staged”). At this stage the cancer cells 
may have been too numerous for the transferred T cells. 
However, all patients with stages below M1c melanoma and 
even some patients with stage M1c melanoma showed at least 
some response to adoptive cell transfer, either complete re-
sponse, partial response, or stable disease. This indicates that 
adoptive cell transfer using patient’s own T cells, combined 
with nonmyeloablative preparative regimen for immunodeple-
tion is an effective treatment for early stages of metastatic 
melanoma patients. 
This trial, in which patients received only nonmyeloablative 
preparative regimen for immunodepletion prior to adoptive 
cell transfer, significantly outperformed the previously men-
tioned trial in which patients received only nonmyeloablative 
preparative regimen for immunodepletion prior to adoptive 
cell transfer. One possible explanation may be that this trial 
used T cells taken from removed portions of the patients own 
tumor, ensuring that the T cells used were highly reactive to 
the patients cancerous cells.
As previously stated, immunodepletion prior to adoptive cell 
transfer increases the effectiveness of the treatment. However, 
immunodepletion effects the entire immune system, which can 
have life threatening side effects. Therefore further study to 
determine key components that effect the effectiveness of 
adoptive cell transfer and how to precisely block them may 
be helpful. 
The most obvious immune element that would reduce the 
effectiveness of adoptive cell transfer is regulatory T cells. 
When developing T cells and B cells, the body has mechanisms 
through which it ensures than no immune cell is released that 
reacts to self-antigens; however, the system is not foolproof. 
Regulatory T cells restrain the few immune cells that get 
through those mechanisms and suppress them ensuring that 













No TBI 43 16 (37) 5 (12) 21 (49)
2 GY TBI 25 8 (32) 5 (20) 13 (52)
12 GY TBI 25 8 (32) 10 (40) 18 (72)
Total 93 32 (34) 20 (22) 52 (56)
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It has been shown that regulatory T cells suppress anti-cancer 
CD 8 T cells in vitro (Antony et. al., 2005). It would be logical 
to hypothesize that regulatory T cells would also effect the T 
cells transferred during adoptive cell transfer. To test for a cor-
relation between regulatory T cells and adoptive cell transfer, 
tumor bearing mice were treated with adoptive cell transfer. 
Some mice were then injected with anti-Thy-1.2 antibody and 
complement to suppress function of regulatory T cells, while 
others were given active regulatory T cells. The results showed 
that when regulatory T cell function was turned off the trans-
ferred T cells destroyed the cancerous cells. However, when 
active regulatory T cells were added the size of the tumors 
continued growing exponentially (North, 1982). This shows 
that regulatory T cells have a large impact on the effectiveness 
of adoptive cell transfer. 
Although regulatory T cells decrease the effectiveness of adop-
tive cell transfer, simply turning them off while leaving the rest 
of the immune system intact would allow surviving immune 
cells that recognize self-antigens to attack patients’ healthy 
cells causing autoimmune disease. 
One method to reduce the effect of regulatory T cells on adop-
tive cell transfer without effecting the entire immune system 
may be to induce apoptosis only in regulatory T cells in close 
proximity to the tumor. This would allow the transferred T 
cells to operate in an environment conducive to their function, 
while allowing regulatory T cells in other areas of the body to 
operate freely avoiding autoimmune disease. 
Recently, it was suggested that the protein FasL-Fc can be used 
to deplete regulatory T cells located only in tumors (Chen et. 
al., 2007). To confine the protein FasL-FC to the tumor, a pro-
tein is incorporated into cell membranes and acts as a trap 
for the Fc portion of FasL-Fc, not allowing it to escape the 
confines of the tumor (Chen, Zheng, Tykocinski, 2000). To test 
this suggestion, tumor bearing mice were injected with FasL-Fc 
in the tumor region. The results showed a significant increase 
in apoptosis of regulatory T cells in the tumors treated with 
FasL-Fc, indicating this may be a viable option to decrease the 
regulatory T cell effect on adoptive cell transfer without effect-
ing the entire immune system (Chen et. al., 2007). 
To test the actual effect of the protein FasL-Fc on adoptive cell 
transfer, tumor bearing mice were treated with both FasL-Fc 
and adoptive cell transfer. The results were a significant retar-
dation of tumor growth in a large portion of mice. Additionally, 
complete tumor regression was seen in 53% of the mice (Chen 
et. al., 2007). This indicates that using the protein FasL-Fc may 
be a viable option to eliminate the effect of regulatory T cells 
on adoptive cell transfer while allowing the immune system to 
operate regularly and without the risk of autoimmune effects. 
To determine the impact of other immune elements on adop-
tive cell transfer, tumor bearing mice were tested and the re-
sults analyzed. In many studies, after irradiation of cancer bear-
ing mice lacking regulatory T cells, effectiveness of adoptive cell 
transfer increased. This indicates that regulatory T cells are not 
the only elements responsible for decreased effectiveness of 
adoptive cell transfer (Gattinoni et. al., 2005). 
One hypothesis is that Natural Killer cells act as sinks for cy-
tokines responsible for survival, proliferation, and function of 
transferred CD 8 T cells (Gattinoni et. al., 2005). Host Natural 
Killer cells, also in need of cytokines, compete for the same 
cytokines necessary to support the transferred T cells lead-
ing to a limited amount of cytokines available to support the 
transferred T cells. To test this hypothesis, tumor bearing mice 
lacking endogenous B cells and T cells, including regulatory T 
cells, were treated with anti-NK1.1 antibody to decrease the 
number of Natural Killer cells to the number found after irra-
diation of the entire immune system. They were then treated 
with adoptive cell transfer and compared to mice not given 
the anti-NK1.1 antibody and treated with adoptive cell trans-
fer. The results showed that removal of Natural Killer cells 
increased the effectiveness of adoptive cell transfer, indicating 
that Natural Killer cells play an important role in the function 
of transferred CD 8 T cells (Gattinoni et. al., 2005). 
One way to avoid the effects of cytokine sinks may be to pre-
cisely determine which cytokines the Natural Killer cells sink, 
and stimulate an increase of their production giving the trans-
ferred T cells access to those cytokines. 
To determine the effects of cytokines on adoptive cell transfer, 
different cytokines were removed and added to tumor bearing 
mice treated with adoptive cell transfer. Results indicated that 
the cytokline IL-7 was needed to maintain survival and con-
tinued growth of transferred T cells, but was not necessary to 
maintain function of the T cells. Conversely, IL-15 was neces-
sary to maintain function, but did not play a part in survival and 
proliferation of transferred T cells. This shows that increasing 
both IL-7 and IL-15 at the same time increases the transferred 
T cells effectiveness against tumors, while decreasing both IL-7 
and IL-15 at the same time would decreases the transferred T 
cells effectiveness against tumors (Gattinoni et. al., 2005). 
These findings indicate that there may be a path by which reg-
ulatory T cells can be eliminated from the area of the tumor 
(Chen et. al., 2007), and transferred CD 8 T cells can be stimu-
lated to proliferate and enhance their effector functions with-




In conclusion, increasing CD 8 T cell count alone is not the most 
effective way to use T cells to fight cancer. Instead immunode-
pletion together with an increase in anti-cancer T cells delivered 
through adoptive cell transfer is an effective approach that has 
been shown to be effective in humans with metastatic mela-
noma. Other factors besides immunodepletion also effect the 
results of adoptive cell transfer such as cytokines, and the origin 
of the T cells injected. The key to adoptive cell transfer success 
with limited side effects, is the balance of all elements involved 
which is a large task and requires further study but does seem 
possible in the future.
However, for now, adoptive cell transfer is still a relatively new 
method of treatment and still requires immunodepletion for 
its effectiveness. This can bring with it its own problems, such 
as an increased risk of infection and a limited ability to fight 
infection. Additionally, most trials of adoptive cell transfer on 
humans have been limited to melanoma patients, making further 
research necessary for it to be used to fight other cancers. To 
that effect, further studies are currently underway to broaden 
this treatment to fight other cancers including, lymphoma, leu-
kemia, and neuroblastoma (Deng et. al., 2014) giving hope to 
cancer patients all over the world.
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